1531 GMT - Novo Nordisk's trial of CagriSema in obese patients with diabetes demonstrated 13.7% weight loss, below investor expectations of around 15% and broadly in line with Eli Lilly's Zepbound drug, Bank of America Securities analysts Sachin Jain and Graham Parry write. The drug had already disappointed in a trial of patients without diabetes. The bank had seen potential for CagriSema to demonstrate superior weight loss to Zepbound, but the difference between the drug's effect on obese patients and obese diabetic patients looks very similar to both Novo Nordisk's current Semaglutide drug and Zepbound. The data therefore unlikely changes the CagriSema debates around commercial positioning and its insufficient differentiation versus high-dose Semaglutide, among others, they say. Shares fall 2.9%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 11, 2025 11:31 ET (15:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。